Developing an Effective Dialogue with the FDA
Moderating an informative conversation surrounding FDA procedures and communication, Emmett Cunningham, Summit Chairman, draws detailed responses from Wiley Chambers and Malvina Eydelman of the FDA. Focusing the discussion around common questions on how best to interact with the FDA, both formally and informally, Emmett helps deliver the specific answers attendees at the 5th Annual Ophthalmology Innovation Summit @ AAO, have been looking to find.
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals.
Malvina B. Eydelman, MD
Dr. Eydelman joined FDA in 1995 and for the last 17 years, has served as the Director of FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices (DOED), and subsequently Director of the FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices (DONED).
Wiley A. Chambers, MD
Wiley A. Chambers, MD, is the Deputy Director of the Division of Transplant and Ophthalmology Products in the Center for Drug Evaluation and Research at the FDA.